Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up

European Neurology

Volumn 56, Issue 1, 2006, Pages 13-16

  Pietrangeli, Alberto ^a   Leandri, Massimo ^b   Terzoli, Edmondo ^a   Jandolo, Bruno ^a   Garufi, Carlo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Colorectal cancer; Neuropathy; Neurotoxicity; Oxaliplatin; Quality of life

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COLORECTAL CANCER; CONTROLLED STUDY; DISTAL PARESTHESIA; DRUG MEGADOSE; DYSESTHESIA; FEMALE; FOLLOW UP; HUMAN; HYPOREFLEXIA; MALE; NEUROLOGIC EXAMINATION; NEUROPATHY; NEUROPHYSIOLOGY; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY;

ACTION POTENTIALS; ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEURAL CONDUCTION; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVES; TIME FACTORS;

EID: 33748490720     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094376     Document Type: Article

References (19)

1. Raymond E, Chaney SG, Taamma A, et al: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
2. Bleiberg H: Oxaliplatin(L-OHP): a new reality in colorectal cancer. Br J Cancer 1998;46:1-3.
3. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al; Multicenter International Study of Oxaliplatin/5-fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
4. Misset JL: Oxaliplatin in practice. Br J Cancer 1998;9:4-7.
5. Lévi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994;86:1608-1617.
6. Garufi C, Pietrangeli A, Brienza S, Aschelter AM, Pace R, Giannarelli D, et al: Electrophysiological evaluation of oxaliplatin neurotoxicity. Proc ASCO 35th Annu Meet, Los Angeles, Calif., June 1999;244a:938.
7. Extra JM, Marty M, Brienza S, Misset JL: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25:13-12.
8. Grothey A: Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005;5(suppl 1):S38-S46.
9. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002;20:1767-1774.
10. Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17.
11. Holmes J, Stanko J, Varchenko M, Ding H, et al: Comparative neurotoxicity of oxaliplatin, cisplatin and ormaplatin in a Wistar rat model. Toxicol Sci 1998;46:342-351.
12. Cascinu S, Catalano V, Cordella L, La Bianca L, Giordani P, Baldelli AM, et al: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo controlled trial. J Clin Oncol 2002;86:3478-3483.
13. Cersosimo RJ: Oxaliplatin-associated neuropathy: review. Ann Pharmacother 2005;39:128-135.
14. Mattioli R, Massaccesi C, Recchia F, et al: High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005;16:1147-1151.
15. Cavaletti G, Marzorati L, Bogliun G, et al: Cisplatin induced peripheral neurotoxicity is dependent on total and single dose intensity. Cancer 1992;69:203-207.
16. Levi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, et al: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994;86:1608-1617.
17. Levi F, Zidani R, Misset JL: Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350:681-686.
18. Giacchetti S, Bjarnason G, Garufi C, Tubiana-Mathieu N, Iacobelli S, Dogliotti R, et al: First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer: 4-day chronomodulated (FFL4-10) versus 2-day FOLFOX2. A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC 05963) (abstract 3526). Proc ASCO 40th Annu Meet, New Orleans, June 2004.
19. Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith RE: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07 (abstract LBA3500). Proc ASCO 41th Annu Meet, Chicago, Ill., June 2005.